TrialInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.

Flonza Isa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.